Long-COVID in Scotland Study: a nationwide, population cohort study

doi:10.21203/rs.3.rs-1656915/v1

Download PDF

Article

Long-COVID in Scotland Study: a nationwide, population cohort study

https://doi.org/10.21203/rs.3.rs-1656915/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 12 Oct, 2022

Read the published version in Nature Communications →

Version 1

posted

You are reading this latest preprint version

BACKGROUND

With increasing numbers of people infected with SARS-CoV-2, a better understanding of long-COVID is required to inform health and social care support.

METHODS

A nationwide, ambidirectional, population cohort was constructed of adults in Scotland with a positive SARS-CoV-2 PCR test from April 2020 to May 2021 and a matched, never infected comparison group. Recovery status, symptoms, quality of life, impaired daily activities, hospitalization and death were ascertained via repeated self-completed questionnaires, at 6, 12 and 18-months follow-up, and linkage to hospitalization and death records.

RESULTS

The cohort comprised 31,486 symptomatic and 1,795 asymptomatic infected individuals, and 62,957 never infected individuals. Of the former, 1,856 (6%) had not recovered and 13,350 (42%) only partially. Lack of recovery was associated with severe (hospitalized) infection, older age, female sex, deprivation, respiratory disease, depression and multimorbidity. Twenty-four persistent symptoms were independently associated with previous infection including breathlessness (OR 3.44, 95% CI 3.29–3.59), palpitations (OR 2.51, OR 2.37–2.67), chest pain (OR 2.10, 95% CI 1.97–2.24), and confusion (OR 2.93, 95% CI 2.78–3.08). Pre-infection vaccination was associated with reduced risk of seven symptoms. Previous symptomatic infection was also associated with poorer quality of life (EQ-5D median 75 vs 80, p < 0.001) and impairment across all daily activities. Asymptomatic infection was not associated with adverse outcomes.

CONCLUSIONS

The sequelae of SARS-CoV-2 infection are wide-ranging and not explained by confounding. The risk of long-COVID is greater following severe infections requiring hospitalization and absent following asymptomatic infection, whilst pre-infection vaccination may be protective.

Cohort studies

COVID-19

natural history

post-acute COVID-19 syndrome

SARS-CoV-2

Whilst most people recover fully from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, some develop long-COVID. With increasing numbers of people having been infected since the start of the pandemic, attention is shifting from managing the acute infection to understanding long-COVID in order to inform the health and social care response. The WHO defined long-COVID as “a history of probable or confirmed SARS-CoV-2 infection … with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis”.¹ The imprecision of this, and other, definitions reflects our poor understanding of the nature of long-COVID and its underlying mechanisms.

A meta-analysis of 63 studies pooled symptom prevalence following laboratory-confirmed SARS-CoV-2 infection.² Sample size ranged from 58 to 1,733 (16,336 in total), with most studies containing fewer than 200 participants. Overall, 53% of people reported one or more symptom beyond 12 weeks following infection. The most common were fatigue, pain/discomfort, shortness of breath, cognitive impairment, and mental health problems. Eighteen studies were judged to be at high risk of bias, and the remaining 45 at moderate risk, due to convenience sampling and unrepresentative study populations. Half of the studies investigated hospitalised cohorts. The only two studies with more than 1,000 participants were a hospitalised cohort and a cohort of health-care workers with mild infection. In a subsequent meta-analysis of 18 studies with at least 12 months follow-up, study samples ranged from 51 to 2,433 (8,591 in total) and 28% of participants reported fatigue/weakness, 22% anxiety, 18% breathlessness, 19% memory loss, 18% concentration difficulties, and 12% insomnia.³ The authors highlighted small sample size, lack of representativeness, and low response rate as limitations. Whilst many long-COVID studies have focused on patients hospitalised with more severe infections, a meta-analysis of 9 studies reported persistent symptoms in up to one-third of people following mild SARS-CoV-2 infection.⁴

This study aimed to address some of the limitations of existing studies by determining the frequency, nature, determinants and impact of long-COVID in the general population using a largescale, nationwide study, including people who had severe, mild and asymptomatic infections and a never infected comparison group, and measuring serial self-reported outcomes as well as outcomes obtained from linkage to routine health records.

STUDY DESIGN

Long-COVID in Scotland Study (Long-CISS) is an ambidirectional, general population cohort. Every adult (> 16 years) in Scotland with a positive PCR test for SARS-CoV-2 from April 2020 to May 2021 was invited to participate along with a comparison group who had had a negative test but never had a positive test, matched 3:1 by age, sex, and area-based socioeconomic deprivation quintile. The National Health Service (NHS) Scotland platform that provides PCR result notifications identified eligible participants and invited them via automated SMS text messages. The study commenced in May 2021 and recruited both retrospectively and prospectively based on existing and new test results respectively. People in the comparison group were reallocated to the infected group if, and when, they had a positive test. The cohort included people with asymptomatic SARS-CoV-2 infection detected, for example, during occupational or travel-related screening. Participants provided electronic consent and study approval was obtained from the West of Scotland Research Ethics Committee (ref. 21/WS/0020) and the Public Benefit and Privacy Panel (ref. 2021 − 0180).

DATA SOURCES

A self-completed online questionnaire collected information on pre-existing health conditions at the time of the index test (first positive test or, for comparison group, most recent negative test) as well as current symptoms, limitations in daily activities and quality of life. Those who had tested positive also provided information on symptoms during the initial infection and current recovery status. Questionnaires were completed 6, 12, and 18 months after the index test. Additional data were obtained through linkage to electronic health records both five years prior their index test and subsequent to the test (up to January 2022) on hospitalizations (Scottish Morbidity Record 01/04), dispensed prescriptions (Prescribing Information System), vaccinations, and death certificates (General Registrar Office).

DEFINITIONS

Infection was defined as a positive PCR recorded on the national database and categorised as symptomatic or asymptomatic based on self-report. Severe infection was defined as hospital admission with ICD-10 code U07.1 between 1 day prior to the test and 2 weeks after. Respondents who reported having had a positive test that was not recorded on the database were excluded from the study as we could not determine whether they were incorrect or had taken the test outside Scotland.

Socioeconomic deprivation was obtained from postcode of residence using the Scottish Index of Multiple Deprivation derived from aggregated data on: income, employment, education, health, access to services, crime and housing.⁵ SARS-CoV-2 variants were defined as dominant if they accounted for ≥95% of cases genotyped that week (https://sars2.cvr.gla.ac.uk/cog-uk/). Pre-existing health conditions were ascertained from self-report, previous hospitalizations and dispensed prescriptions. Respiratory disease was defined as International Classification of Diseases 10 (ICD10) codes J40-J47, J98.2 or J98.3, or bronchodilators, inhaled corticosteroids, cromoglycate, leukotriene or phosphodiesterase type-4 inhibitor (British National Formulary (BNF) 3.1–3.3), or self-report. Coronary heart disease was defined as ICD10 codes I11.0, I13.0, I13.2, I20-I25 (excluding I24.1), I50, T82.2, or Z95.5, or self-report. Depression was defined as ICD10 codes F30-F33, or anti-depressant, hypnotic or anxiolytic (BNF 4.1;4.3), or self-report. Diabetes was defined as ICD10 codes E10-E14, G590, G632, H280, H360, M142, N083, O240-O243 or self-report.⁶ The total number of self-reported health conditions was categorised as 0, 1, 2–3, or ≥4.

OUTCOMES

The outcomes measured were 26 symptoms (harmonised with the ISARIC questionnaire),⁷ limitations across 7 activities of daily living, health-related quality of life (using EQ-5D), hospitalization, admission to an intensive care unit (ICU), and all-cause mortality in the whole cohort, as well as recovery status (full, partial or none) in the symptomatic infection group. Hospitalization was defined as a hospital admission occurring at least two weeks following the index test, to exclude admissions related to the acute infection. Delayed recovery was defined as participants with previous symptomatic infection who reported no/partial recovery at their first follow-up but improvement at subsequent follow-up; no to partial/full recovery or partial to full recovery. Relapse was defined as participants with previous symptomatic infections who reported full/partial recovery at their first follow-up but a deterioration at subsequent follow-up; full to partial/no recovery or partial to no recovery.

STATISTICAL ANALYSES

Baseline characteristics and crude outcomes broken down by infection status (symptomatic, asymptomatic or never infected) were summarized using frequencies/percentages and medians/inter-quartile ranges for categorical and continuous variables and compared using chi-square tests and Mann-Whitney U tests respectively. A heat map was produced of symptom clustering at follow-up. Separate binary logistic regression models were run in the whole cohort to determine the association between infection status and each outcome (symptoms, limitations in daily activities, hospitalization, ICU admission, death), using never infected as the referent group. The models were run univariately, then adjusted incrementally for: socioeconomic factors (age, sex, ethnic group, deprivation); pre-existing health conditions (count, respiratory and coronary heart disease, depression, diabetes); vaccination status; and dominant SARS-CoV-2 variant. In the symptomatic infection group, the same models were run to determine the factors associated with these outcomes and recovery status. All analyses were performed using Stata v16.

COHORT CHARACTERISTICS

Overall, 102,473 (16%) of the 638,125 people invited participated: 33,281 (20%) of the 162,957 people who had a positive test, and 69,192 (15%) of the 475,168 invited following only negative tests. We excluded 6,235 participants who had only negative tests recorded but self-reported they had tested positive. Therefore, the study cohort comprised 96,238 participants. Their median age at baseline was 45 (IQR 31-56) years, 39% were male, 91% white, 30% had at least one pre-existing health condition and 16% at least two; and 4% had received at least one COVID-19 vaccination dose prior to their index test (Table 1).

SYMPTOMS DURING ACUTE INFECTION

Among the 33,281 participants who had a positive test, 31,486 (95%) were symptomatic at the time of infection; 1,208 (4%) had one symptom, 1,999 (6%) had two, 2,493 (8%) had three, and 25,786 (82%) had more than three. Overall, 83% reported fatigue at the time of acute infection, 64% headache, 63% change in taste, 63% myalgia, 60% change in smell, 54% cough, 52% fever, 45% breathlessness, 41% loss of appetite, 38% joint pain, 31% sore throat, 23% diarrhea, 21% chest pain, 20% runny nose, 15% abdominal pain, 13% confusion, 13% hoarse voice, 9% hair loss, 8% ear pain, 2% reduced consciousness, and 0.3% seizures. Of those who reported symptom duration, 7,259 (23%) reported <1 week, 13,710 (44%) 1-4 weeks, and 10,489 (33%) >4 weeks.

OUTCOMES

Of the 96,238 participants, all had at least 6 months follow-up; 19,491 (20%) completed questionnaires at 12 months follow-up and 809 (1%) at eighteen months. At their most recent follow-up, 1,856 (6%) of the 31,486 people who had had symptomatic infections reported that they had not recovered and 13,350 (42%) that they had only partially recovered. Among the 1,342 people whose infection required hospitalization, the figures were 217 (16%) and 797 (59%) respectively and among the 30,096 managed in the community, they were 1,639 (5%) and 12,553 (42%) respectively.

For the 3,941 with serial questionnaire data there was little change in the overall breakdown; at their first follow-up, 316 (8%) had not recovered and 1,866 (47%) had only partially recovered, compared to 324 (8%) and 1,806 (46%) respectively at their most recent follow-up. However, there was some cross-over between groups; 1,453 (37%) remained fully recovered, 1,372 (35%) remained partially recovered, and 175 (4%) continued to report no recovery, while 494 (13%) reported delayed recovery (improvement over time), and 447 (11%) reported relapse (deterioration over time).

Of the 21,525 people with ongoing symptoms following symptomatic infection, the most common were tiredness, headache and muscle aches/weakness (Table 2). However, symptoms were also common among people never infected. Compared with the latter, people who had previous symptomatic infection were significantly more likely to report 24 of the 26 symptoms at follow-up after adjusting for potential confounders (Table 3). After changes in smell and taste, the largest effect sizes were observed for cardiovascular symptoms (breathlessness, chest pain and palpitations) and confusion (Table 3). People with previous symptomatic infection were also more likely to have multiple (³3) symptoms than people never infected (14,236 (45%) vs 19,613 (31%)). There was weak evidence of clustering of musculoskeletal and neuropsychological symptoms following previous symptomatic infection (Supplementary Figure 1).

Routine data were available until January 2022 providing a median (IQR) of 6 (5-8) months follow-up. People who had previous symptomatic infection were not at significantly increased risk of all-cause hospitalization (fully adjusted HR 1.01, 95% CI 0.97-1.05, p=0.575), ICU admission (fully adjusted HR 1.21, 95% CI 0.86-1.71, p=0.268) or all-cause mortality (fully adjusted HR 0.63, 95% CI 0.38-1.02, p=0.061). However, they had a median EQ-5D score of 75 (IQR 60-89) at latest questionnaire follow-up compared with 80 (IQR 63-90) for people never infected (p<0.001). Similarly, people who had had symptomatic infection were significantly more likely to report impaired mobility, housework/chores, working/studying, washing/dressing, exercise/sport, hobbies and relationships after adjusting for potential confounders (Table 4). Asymptomatic SARS-CoV-2 infection was not associated with increased risk of current symptoms, impaired daily activities, reduced quality of life, hospitalization, ICU admission or death.

FACTORS ASSOCIATED WITH OUTCOMES

Following previous symptomatic infection, lack of complete recovery was associated with more severe (hospitalized) initial infection, older age, female sex, deprivation, white ethnicity, and pre-existing health conditions, including respiratory disease and depression (Table 5). Compared to unvaccinated people, people vaccinated prior to symptomatic infection were less likely to report persistent change in smell (HR 0.58, 0.44-0.75), change in taste (HR 0.60, 95% CI 0.46-0.78), problems hearing (HR 0.62, 95% CI 0.45-0.85), poor appetite (HR 0.73, 95% CI 0.53-0.99), balance problems (HR 0.75, 95% CI 0.56-0.99), confusion/difficulty concentrating (HR 0.76, 95% CI 0.61-0.94), and anxiety/depression (HR 0.78, 95% CI 0.65-0.94) at their latest follow-up after adjustment for potential confounders.

Between 6 and 18 months following symptomatic SARS-CoV-2 infection, almost half of those infected reported no, or incomplete, recovery. Whilst recovery status remained constant over follow-up for most, 13% reported improvement over time and 11% deterioration. Symptomatic SARS-CoV-2 infection was associated with a wide range of persistent symptoms, impaired daily activities and reduced health-related quality of life, independent of sociodemographic factors and pre-existing health conditions. The strongest associations were observed for cardiovascular symptoms (breathlessness, chest pain and palpitations) and confusion. Lack of recovery was associated with more severe infection, older age, female gender, deprivation, pre-existing respiratory disease and multimorbidity but pre-infection vaccination was associated with reduced risk of some persistent symptoms. We found no evidence of sequelae following asymptomatic infection.

Our finding of impaired daily activities is consistent with previous studies. In a meta-analysis of 12 studies covering 4,828 participants previously infected by SARS-CoV-2, 35% had problems with mobility, 8% with personal care, 42% pain/discomfort, and 38% anxiety/depression.¹⁰ Similarly, in a global social media survey of 1,020 confirmed and 2,742 suspected previous COVID-19 cases, 45% reported ongoing impact on their ability to work.¹¹ In line with our findings, previous studies have reported that women, older and more deprived people, and those with pre-existing health problems were less likely to recover completely from COVID-19.^8,9

Of eight studies that assessed the effectiveness of pre-infection vaccination on long-COVID,¹² six (two cohort, two case-control, two cross-sectional) reported fewer symptoms 1–6 months following infection among those fully vaccinated,^13–18 including fatigue, headache, muscle weakness/pain, breathlessness, dizziness, and change in smell.^15,18 Our findings differ from previous studies^{14–16, 18} in suggesting possible protection against persistent symptoms from even partial vaccination. Three studies have suggested that, among unvaccinated people, post infection vaccination may also reduce the risk or severity of long-COVID,^17,19,20 especially if given early following infection .¹⁷

As a general population study, our findings provide a better indication of the overall risk and burden of long-COVID than hospitalised cohorts. Inclusion of asymptomatic infections enabled us to demonstrate that long-COVID is specific to people with symptomatic infection. Incomplete ascertainment of all cases of COVID-19 was inevitable due to lack of PCR testing at the beginning of the pandemic, followed by a gradual increase in testing capacity and therefore changes in testing criteria. Risk of misclassification was reduced by using a composite definition of previous infection, requiring both laboratory-confirmation and self-report, and excluding people who reported a previous positive test that was not on the database. Since the never infected group will include some people with asymptomatic infection or symptomatic infection prior to testing becoming available our findings may under-estimate the true magnitude of association between SARS-CoV-2 infection and ongoing health problems.

Our cohort included a large sample (n = 33,281) of people previously infected and the response rate of 16% overall and 20% among people who had symptomatic infection was high for this type of study. However, recruitment may have been lower in some sub-groups. For example, the questionnaire was written in English and accessed via a web-based app and therefore may have been inaccessible to people without internet access or without English as their first language. Formal and informal carers were permitted to assist respondents in completing the questionnaire. It is possible that people with persistent health problems may have been more motivated to participate.

Symptoms are common in the general population. The three most common symptoms among people previously infected were also reported by 16%-32% of people never infected. Therefore, inclusion of an uninfected comparison group enabled us to demonstrate that the outcomes were not due to confounding. We matched our uninfected comparison group 3:1 at the time of invitation; allowing for a lower response rate among uninfected individuals and attrition due to subsequent infection. Serial outcome measurements in a sub-group of 3,941 respondents enabled us to investigate the trajectory of long-COVID over time. Very few people had been fully vaccinated pre-infection. However, sufficient had received a single dose to demonstrate some evidence of protection against persistent symptoms. The non-significant lower risk of death following symptomatic infection is likely to reflect the fact that our study recruited people who had survived at least six months following infection.

In conclusion, 6–18 months following symptomatic SARS-CoV-2 infection, adults were at greater risk of a diverse group of symptoms, poorer quality of life and wide-ranging impairment of their daily activities, that could not be explained by confounding. Sequelae were more likely following severe infection and were not observed following asymptomatic infection and pre-infection vaccination may be protective.

Acknowledgements

We are grateful to Public Health Scotland and HDR-UK for providing and linking secondary data, the National Safe Haven for providing a secure analytical environment, Storm-ID for administering invitations and data collection, the Scottish Government for supporting the study launch, and the University of Glasgow, College of Medical, Veterinary and Life Sciences PPIE (Patient and Public Involvement and Engagement) and COVID-19 PPIE groups for their contributions to study design and recruitment.

Funding

Long-CISS was funded by the Chief Scientist Office (ref. COV/LTE/20/06) and Public Health Scotland. NLM is supported by a Chair Award (CH/F/21/90010), a Programme Grant (RG/20/10/34966) and a Research Excellence Award (RE/18/5/34216) from the British Heart Foundation.

WHO. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 20212021. (https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1)
Domingo FR, Waddell LA, Cheung AM, et al. Prevalence of long-term effects in individuals diagnosed with COVID-19: an updated living systematic review. medRxiv 2021. https://doi.org/10.1101/2021.06.03.21258317
Han Q, Zheng B, Daines L, Sheikh A. Long-Term Sequelae of COVID-19: A Systematic Review and Meta-Analysis of One-Year Follow-Up Studies on Post-COVID Symptoms. Pathogens 2022;11.
van Kessel SAM, Olde Hartman TC, Lucassen P, van Jaarsveld CHM. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract 2022;39:159–67.
Scottish Index of Multiple Deprivation 2020. (https://www.gov.scot/collections/scottish-index-of-multiple-deprivation-2020/.)
HDR-UK Phenotype Library. (https://phenotypes.healthdatagateway.org/phenotypes/)
Sigfrid L, Cevik M, Jesudason E, et al. What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? - A harmonised, global longitudinal observational study protocol. BMJ Open. 2021;11(3):e043887
Cabrera Martimbianco AL, Pacheco RL, Bagattini AM, Riera R. Frequency, signs and symptoms, and criteria adopted for long COVID-19: A systematic review. Int J Clin Pract 2021;75:e14357.
Poudel AN, Zhu S, Cooper N, et al. Impact of Covid-19 on health-related quality of life of patients: A structured review. PLoS One 2021;16:e0259164.
Malik P, Patel K, Pinto C, et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)-A systematic review and meta-analysis. J Med Virol 2022;94:253–62.
Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021;38:101019.
Harrison S, Walters B, Simmons Z, Cook M, Clark R. The effectiveness of vaccination against long COVID: A rapid evidence briefing. In: UK Health Security Agency DoHaSS, ed. London2022. (https://ukhsa.koha-ptfs.co.uk/cgi-bin/koha/opac-detail.pl?biblionumber=64359)
Aly-Aly Z, Bowe B, Xie Y. Long Covid after Breakthrough COVID-19: the post-acute sequelae of breakthrough COVID-19. ResearchSquare 2021. (https://www.researchsquare.com/article/rs-1062160/v1)
Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis 2022;22:43–55.
Kuodi P, Gorelik Y, Zayyad H, et al. Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients infected between March 2020 and November 2021. medRxiv 2022. (https://doi.org/10.1101/2022.01.05.22268800)
Senjam SS, Balhara YPS, Kumar P, et al. Assessment of Post COVID-19 Health Problems and its Determinants in North India: A descriptive cross section study. medRxiv 2021. (https://doi.org/10.1101/2021.10.03.21264490)
Simon MA, Luginbuhl RD, Parker R. Reduced Incidence of Long-COVID Symptoms Related to Administration of COVID-19 Vaccines Both Before COVID-19 Diagnosis and Up to 12 Weeks After. medRxiv 2021. (https://doi.org/10.1101/2021.11.17.21263608)
Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections. medRxiv 2021. (https://doi.org/10.1101/2021.10.26.21265508)
Arnold DT, Milne A, Samms E, Stadon L, Maskell NA, Hamilton FW. Are vaccines safe in patients with Long COVID? A prospective observational study. medRxiv 2021. (https://doi.org/10.1101/2021.03.11.21253225)
Ayoubkhani D, Bermingham C, Pouwels, KB, et al. Changes in the trajectory of Long Covid symptoms following COVID-19 vaccination: community-based cohort study. medRxiv 2021. (https://doi.org/10.1101/2021.12.09.21267516)

Table 1. Characteristics of study participants by infection status

	Never infected N=62,957	Asymptomatic infection N=1,795	Symptomatic infection N=31,486	P value	Overall N=96,238

	Med (IQR)	Med (IQR)	Med (IQR)		Med (IQR)
Age (years)	45 (31-56)	43 (28-57)	44 (30-56)	<0.001	45 (31-56)

Sex	N (%)	N (%)	N (%)		N (%)
Female	37,422 (59)	957 (53)	20,202 (64)	<0.001	58,581 (61)
Male	25,535 (41)	838 (47)	11,284 (36)	<0.001	37,657 (39)
SIMD
1 (most deprived)	14,906 (24)	504 (28)	7,658 (24)	<0.001	23,068 (24)
2	13,594 (22)	418 (23)	6,782 (22)		20,794 (22)
3	11,344 (18)	291 (16)	5,656 (18)		17,291 (18)
4	11,632 (18)	289 (16)	5,717 (18)		17,638 (18)
5 (least deprived)	11,481 (18)	293 (16)	5,673 (18)		17,447 (18)
Ethnic group
White	56,729 (90)	1,207 (67)	29,286 (93)	<0.001	87,222 (91)
South Asian	881 (1)	44 (2)	724 (2)		1,649 (2)
Black	322 (1)	15 (1)	185 (1)		522 (1)
Other	1,058 (2)	16 (1)	488 (2)		1,562 (2)
Missing	3,967 (6)	513 (29)	803 (3)		5,283 (5)
Number of pre-existing health conditions
0	43,008 (68)	1,512 (84)	22,764 (72)	<0.001	67,284 (70)
1	8,616 (14)	152 (8)	4,052 (13)		12,820 (13)
2-3	8,975 (14)	111 (6)	3,801 (12)		12,887 (13)
≥4	2,358 (4)	20 (1)	869 (3)		3,247 (4)
Pre-existing health conditions
Arthritis	4,063 (6)	56 (3)	1,759 (6)	<0.001	5,878 (6)
Asthma/bronchitis/COPD	15,128 (24)	356 (20)	6,715 (21)	<0.001	22,199 (23)
Cancer	969 (2)	13 (1)	304 (1)	<0.001	1,286 (1)
CHD	2,144 (3)	32 (2)	882 (3)	<0.001	3,058 (3)
Cystic fibrosis	21 (0)	£10	£10	0.238	£10
Deep vein thrombosis	221 (0)	£10	83 (0)	0.077	£10
Depression/anxiety	29,996 (48)	657 (37)	13,501 (43)	<0.001	44,154 (46)
Diabetes	3,016 (4)	64 (4)	1,380 (4)	0.002	4,460 (5)
High blood pressure	5,499 (9)	80 (4)	2,631 (8)	<0.001	8,210 (9)
HIV	73 (0)	£10	33 (0)	0.347	£10
Home oxygen	34 (0)	£10	16 (0)	0.609	£10
Kidney disease	426 (1)	£10	166 (1)	0.001	£10
Liver disease	299 (0)	£10	89 (0)	<0.001	£10
Neurological condition	1,565 (2)	17 (1)	505 (2)	<0.001	2,087 (2)
Overweight	5,832 (9)	56 (3)	2,568 (8)	<0.001	8,456 (9)
Obese	2,302 (4)	20 (1)	928 (3)	<0.001	3,250 (3)
Pulmonary embolism	227 (0)	£10	87 (0)	0.005	£10
Pulmonary fibrosis	52 (0)	£10	14 (0)	0.058	£10
Stroke	536 (1)	£10	198 (1)	<0.001	£10
Number of vaccinations
0	60,230 (96)	1,687 (94)	30,440 (97)	<0.001	92,357 (96)
1	2,361 (4)	95 (5)	979 (3)		3,435 (4)
2-4	366 (1)	13 (1)	67 (0)		446 (0)
Variant period
Pre VOC	28,730 (46)	803 (45)	15,213 (48)	<0.001	44,746 (47)
No dominant (1)	25,681 (41)	705 (39)	12,448 (40)		38,834 (40)
Alpha	6,863 (11)	238 (13)	3,064 (10)		10,165 (11)
No dominant (2)	1,683 (3)	49 (3)	761 (2)		2,493 (3)

N number; Med median; IQR inter-quartile range; SIMD Scottish Index of Multiple Deprivation; COPD chronic obstructive pulmonary disease; CHD coronary heart disease; VOC variant of concern

Table 2. Crude outcomes of participants by infection status

	Never infected N=62,957	Asymptomatic infection N=1,795	Symptomatic infection N=31,486	P value	Overall N=96,238
Symptoms in last week	N (%)	N (%)	N (%)		N (%)
Tiredness	19,873 (32)	147 (8)	13,891 (44)	<0.001	33,911 (35)
Headache	13,659 (22)	97 (5)	7,658 (24)	<0.001	21,414 (22)
Muscle aches/weakness	10,118 (16)	75 (4)	7,559 (24)	<0.001	17,752 (18)
Joint pain	8,821 (14)	69 (4)	5,865 (19)	<0.001	14,755 (15)
Breathless	5,078 (8)	50 (3)	6,327 (21)	<0.001	11,455 (12)
Anxious/depressed	9,056 (14)	69 (4)	6,180 (20)	<0.001	15,305 (16)
Confused/difficulty concentrating	3,187 (5)	23 (1)	3,927 (12)	<0.001	7,137 (7)
Sleep problems	10,842 (17)	90 (5)	7,487 (24)	<0.001	18,419 (19)
Dry cough	4,820 (8)	47 (3)	3,556 (11)	<0.001	8,423 (9)
Cough with phlegm	5,945 (9)	68 (4)	3,198 (10)	<0.001	9,211 (10)
Change in taste	1,048 (2)	11 (1)	2,730 (9)	<0.001	3,789 (4)
Change in smell	816 (1)	14 (1)	3,278 (10)	<0.001	4,108 (4)
Problems hearing	2,024 (3)	16 (1)	1,614 (5)	<0.001	3,654 (4)
Problems with eyesight	2,300 (4)	17 (1)	2,048 (7)	<0.001	4,365 (5)
Pins and needles	4,043 (6)	33 (2)	3,265 (10)	<0.001	7,341 (8)
Chest pain	2,125 (3)	25 (1)	2,017 (6)	<0.001	4,167 (4)
Palpitations	2,355 (4)	19 (1)	2,660 (8)	<0.001	5,034 (5)
Poor appetite	3,145 (5)	18 (1)	1,682 (5)	<0.001	4,845 (5)
Abdominal pain	4,161 (7)	24 (1)	2,105 (7)	<0.001	6,290 (7)
Sickness/vomiting	3,713 (6)	16 (1)	1,858 (6)	<0.001	5,587 (6)
Diarrhea	4,718 (7)	24 (1)	2,468 (8)	<0.001	7,210 (7)
Constipation	2,444 (4)	19 (1)	1,416 (5)	<0.001	3,879 (4)
Weight loss	821 (1)	£10	629 (2)	<0.001	£10
Dizzy/blackouts/fits	2,033 (3)	18 (1)	1,503 (5)	<0.001	3,554 (4)
Balance problems	2,133 (3)	11 (1)	1,799 (6)	<0.001	3,943 (4)
Skin rash	1,726 (3)	19 (1)	1,202 (4)	<0.001	2,947 (3)
No symptoms now	29,316 (47)	1,428 (80)	9,961 (32)	<0.001	40,705 (42)
Difficulties with activities of daily living
Walking; getting around	8,359 (13)	98 (5)	5,787 (18)	<0.001	14,244 (15)
Housework; DIY; chores	8,185 (13)	72 (4)	6,178 (20)	<0.001	14,435 (15)
Working; studying	7,026 (11)	57 (3)	6,181 (20)	<0.001	13,264 (14)
Washing; dressing	3,917 (6)	35 (2)	1,829 (6)	<0.001	5,781 (6)
Exercise; sport	8,859 (14)	85 (5)	7,939 (25)	<0.001	16,883 (18)
Hobbies	4,182 (7)	38 (2)	3,142 (10)	<0.001	7,362 (8)
Relationships	4,735 (8)	51 (3)	3,191 (10)	<0.001	7,977 (8)
EQ-5D	N=59,026	N=1,289	N=30,723		N=91,038
Median (IQR)	80 (63-90)	90 (75-100)	75 (60-89)	<0.001	78 (61-90)
Admitted to hospital	6,409 (10)	141 (8)	3,058 (9)	0.001	9,608 (10)
Admitted to ICU	93 (0)	£10	53 (0)	0.577	£10
Died	72 (0)	£10	21 (0)	0.060	£10

N number; DIY do-it-yourself; IQR inter-quartile range; ICU intensive care uni

Table 3. Univariate and multivariate binary logistic regression analyses of the associations between previous symptomatic SARS-CoV-2 infection and current symptoms, referent to people never infected

	Univariate		Model 1		Model 2		Model 3		Model 4		Model 5
	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
Sensory
Change in taste	5.61 (5.22,6.03)	<0.001	5.48 (5.10,5.90)	<0.001	5.70 (5.30,6.13)	<0.001	5.70 (5.30,6.13)	<0.001	5.69 (5.29,6.13)	<0.001	5.69 (5.29,6.12)	<0.001
Change in smell	8.85 (8.19,9.57)	<0.001	8.64 (7.99,9.34)	<0.001	8.81 (8.14,9.53)	<0.001	8.78 (8.12,9.50)	<0.001	8.79 (8.12,9.51)	<0.001	8.76 (8.10,9.48)	<0.001
Problems hearing	1.63 (1.52,1.74)	<0.001	1.62 (1.51,1.73)	<0.001	1.75 (1.64,1.88)	<0.001	1.75 (1.64,1.88)	<0.001	1.75 (1.64,1.88)	<0.001	1.75 (1.64,1.88)	<0.001
Problems with eyesight	1.83 (1.73,1.95)	<0.001	1.83 (1.72,1.94)	<0.001	1.99 (1.87,2.12)	<0.001	1.99 (1.87,2.12)	<0.001	1.99 (1.87,2.12)	<0.001	1.99 (1.87,2.12)	<0.001
Pins and needles	1.69 (1.61,1.77)	<0.001	1.63 (1.56,1.71)	<0.001	1.80 (1.71,1.89)	<0.001	1.80 (1.71,1.89)	<0.001	1.80 (1.71,1.89)	<0.001	1.80 (1.71,1.89)	<0.001
Cardiorespiratory
Chest pain	1.96 (1.84,2.09)	<0.001	1.91 (1.80,2.04)	<0.001	2.10 (1.97,2.24)	<0.001	2.11 (1.98,2.24)	<0.001	2.10 (1.97,2.24)	<0.001	2.10 (1.97,2.24)	<0.001
Palpitations	2.37 (2.24,2.51)	<0.001	2.28 (2.15,2.41)	<0.001	2.51 (2.37,2.66)	<0.001	2.51 (2.37,2.67)	<0.001	2.51 (2.37,2.67)	<0.001	2.51 (2.37,2.67)	<0.001
Breathlessness	2.87 (2.75,2.98)	<0.001	2.88 (2.77,3.00)	<0.001	3.44 (3.30,3.59)	<0.001	3.44 (3.30,3.59)	<0.001	3.44 (3.30,3.59)	<0.001	3.44 (3.29,3.59)	<0.001
Dry cough	1.54 (1.47,1.61)	<0.001	1.51 (1.44,1.58)	<0.001	1.59 (1.52,1.66)	<0.001	1.59 (1.52,1.66)	<0.001	1.59 (1.52,1.66)	<0.001	1.59 (1.52,1.66)	<0.001
Cough with phlegm	1.08 (1.04,1.13)	<0.001	1.07 (1.02,1.12)	0.003	1.15 (1.09,1.20)	<0.001	1.15 (1.09,1.20)	<0.001	1.15 (1.10,1.20)	<0.001	1.15 (1.09,1.20)	<0.001
Gastrointestinal
Poor appetite	1.07 (1.01,1.14)	0.023	1.03 (0.97,1.10)	0.332	1.14 (1.07,1.21)	<0.001	1.14 (1.07,1.21)	<0.001	1.14 (1.07,1.21)	<0.001	1.14 (1.07,1.21)	<0.001
Abdominal pain	1.01 (0.96,1.07)	0.657	0.96 (0.91,1.01)	0.142	1.05 (0.99,1.11)	0.095	1.05 (0.99,1.11)	0.083	1.05 (0.99,1.11)	0.088	1.05 (0.99,1.11)	0.082
Sickness/vomiting	1.00 (0.94,1.06)	0.984	0.95 (0.90,1.01)	0.075	1.04 (0.98,1.10)	0.194	1.04 (0.98,1.10)	0.178	1.04 (0.98,1.10)	0.183	1.04 (0.98,1.10)	0.179
Diarrhea	1.05 (0.99,1.10)	0.060	1.02 (0.96,1.07)	0.562	1.10 (1.05,1.16)	<0.001	1.10 (1.05,1.16)	<0.001	1.10 (1.05,1.16)	<0.001	1.10 (1.05,1.16)	<0.001
Constipation	1.17 (1.09,1.25)	<0.001	1.12 (1.04,1.19)	0.001	1.23 (1.15,1.32)	<0.001	1.23 (1.15,1.32)	<0.001	1.23 (1.15,1.32)	<0.001	1.23 (1.15,1.32)	<0.001
Musculoskeletal
Muscle aches/weakness	1.65 (1.60,1.71)	<0.001	1.63 (1.57,1.68)	<0.001	1.80 (1.73,1.86)	<0.001	1.79 (1.73,1.86)	<0.001	1.79 (1.73,1.86)	<0.001	1.79 (1.73,1.85)	<0.001
Joint pain	1.40 (1.35,1.46)	<0.001	1.40 (1.35,1.46)	<0.001	1.57 (1.51,1.64)	<0.001	1.57 (1.51,1.64)	<0.001	1.57 (1.51,1.64)	<0.001	1.57 (1.51,1.64)	<0.001
Neurological/mental health
Headache	1.16 (1.12,1.20)	<0.001	1.09 (1.06,1.13)	<0.001	1.16 (1.12,1.20)	<0.001	1.16 (1.12,1.20)	<0.001	1.16 (1.12,1.20)	<0.001	1.16 (1.12,1.20)	<0.001
Anxious/depressed	1.45 (1.40,1.51)	<0.001	1.38 (1.33,1.43)	<0.001	1.59 (1.53,1.65)	<0.001	1.58 (1.53,1.65)	<0.001	1.58 (1.52,1.64)	<0.001	1.58 (1.52,1.64)	<0.001
Confused/difficulty concentrating	2.67 (2.54,2.81)	<0.001	2.59 (2.47,2.72)	<0.001	2.92 (2.78,3.07)	<0.001	2.93 (2.79,3.08)	<0.001	2.92 (2.78,3.07)	<0.001	2.93 (2.78,3.08)	<0.001
Sleep problems	1.50 (1.45,1.55)	<0.001	1.45 (1.41,1.50)	<0.001	1.59 (1.54,1.65)	<0.001	1.59 (1.54,1.65)	<0.001	1.59 (1.54,1.65)	<0.001	1.59 (1.54,1.65)	<0.001
Dizzy/blackouts/fits	1.50 (1.40,1.61)	<0.001	1.43 (1.33,1.53)	<0.001	1.58 (1.47,1.69)	<0.001	1.58 (1.47,1.69)	<0.001	1.58 (1.47,1.69)	<0.001	1.58 (1.47,1.69)	<0.001
Balance problems	1.73 (1.62,1.84)	<0.001	1.72 (1.61,1.83)	<0.001	1.94 (1.81,2.07)	<0.001	1.94 (1.82,2.08)	<0.001	1.94 (1.81,2.07)	<0.001	1.94 (1.82,2.07)	<0.001
Non-specific
Tiredness	1.71 (1.66,1.76)	<0.001	1.65 (1.60,1.69)	<0.001	1.80 (1.75,1.86)	<0.001	1.80 (1.75,1.86)	<0.001	1.80 (1.75,1.85)	<0.001	1.80 (1.75,1.85)	<0.001
Weight loss	1.54 (1.39,1.71)	<0.001	1.51 (1.36,1.68)	<0.001	1.64 (1.47,1.82)	<0.001	1.64 (1.47,1.82)	<0.001	1.64 (1.47,1.82)	<0.001	1.64 (1.47,1.82)	<0.001
Skin rash	1.41 (1.31,1.52)	<0.001	1.37 (1.27,1.47)	<0.001	1.44 (1.33,1.55)	<0.001	1.44 (1.33,1.55)	<0.001	1.44 (1.33,1.55)	<0.001	1.43 (1.33,1.55)	<0.001
No symptoms now	0.53 (0.52,0.55)	<0.001	0.55 (0.54,0.57)	<0.001	0.50 (0.48,0.51)	<0.001	0.50 (0.48,0.51)	<0.001	0.50 (0.48,0.51)	<0.001	0.50 (0.48,0.51)	<0.001

Model 1 - adjusted for age, sex, ethnicity and SIMD quintile; Model 2 - further adjusted for baseline comorbidity count and asthma/bronchitis/COPD, CHD, depression, and diabetes; Model 3 – model 2 further adjusted for variant period; Model 4 - model 2 further adjusted for vaccination status; Model 5 – model 2 further adjusted for variant period and vaccination status

OR odds ratio; CI confidence interval

Table 4. Univariate and multivariate binary logistic regression analyses of the associations between previous symptomatic SARS-CoV-2 infection and current difficulties in activities of daily living, referent to people never infected

	Univariate		Model 1		Model 2		Model 3		Model 4		Model 5
	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
Walking; getting around	1.47 (1.42,1.53)	<0.001	1.47 (1.41,1.52)	<0.001	1.81 (1.73,1.88)	<0.001	1.81 (1.73,1.88)	<0.001	1.81 (1.73,1.88)	<0.001	1.81 (1.73,1.88)	<0.001
Housework; DIY; chores	1.63 (1.58,1.69)	<0.001	1.59 (1.53,1.65)	<0.001	1.97 (1.89,2.05)	<0.001	1.97 (1.90,2.06)	<0.001	1.97 (1.89,2.05)	<0.001	1.97 (1.90,2.06)	<0.001
Working; studying	1.94 (1.87,2.02)	<0.001	1.85 (1.78,1.92)	<0.001	2.09 (2.01,2.17)	<0.001	2.09 (2.01,2.17)	<0.001	2.09 (2.01,2.17)	<0.001	2.09 (2.01,2.17)	<0.001
Washing; dressing	0.93 (0.88,0.98)	0.012	0.89 (0.84,0.94)	<0.001	1.07 (1.00,1.14)	0.036	1.07 (1.01,1.14)	0.034	1.07 (1.00,1.14)	0.037	1.07 (1.00,1.14)	0.037
Exercise; sport	2.06 (1.99,2.13)	<0.001	2.00 (1.94,2.07)	<0.001	2.34 (2.26,2.43)	<0.001	2.34 (2.26,2.43)	<0.001	2.34 (2.26,2.43)	<0.001	2.34 (2.26,2.43)	<0.001
Hobbies	1.56 (1.48,1.64)	<0.001	1.50 (1.43,1.58)	<0.001	1.76 (1.67,1.85)	<0.001	1.76 (1.67,1.85)	<0.001	1.76 (1.67,1.85)	<0.001	1.76 (1.67,1.85)	<0.001
Relationships	1.39 (1.32,1.45)	<0.001	1.32 (1.26,1.39)	<0.001	1.54 (1.47,1.62)	<0.001	1.54 (1.47,1.62)	<0.001	1.54 (1.46,1.62)	<0.001	1.54 (1.47,1.62)	<0.001

OR odds ratio; CI confidence interval; DIY do-it-yourself

Table 5. Multivariate logistic regression analysis of the factors associated with no or partial recovery, referent to full recovery, among people with previous symptomatic SARS-CoV-2 infection

		No recovery N=1,856 OR (95% CI)	Partial recovery N=13,350 OR (95% CI)
Age		1.01 (1.01,1.02)	1.01 (1.00,1.01)
Sex	Female	1	1
Sex	Male	0.69 (0.62,0.78)	0.67 (0.63,0.70)
Ethnicity	White	1	1
	South Asian	0.56 (0.37,0.86)	0.57 (0.48,0.68)
	Black	0.62 (0.31,1.25)	0.41 (0.29,0.59)
	Other	0.38 (0.21,0.68)	0.54 (0.44,0.66)
	Missing	0.61 (0.41,0.89)	0.79 (0.68,0.92)
SIMD quintile	1 (most deprived)	1	1
	2	0.82 (0.71,0.94)	0.95 (0.88,1.02)
	3	0.63 (0.54,0.73)	0.89 (0.82,0.96)
	4	0.53 (0.45,0.62)	0.78 (0.73,0.84)
	5 (least deprived)	0.40 (0.34,0.48)	0.67 (0.62,0.72)
Baseline morbidity count	0	1	1
	1	1.23 (1.06,1.44)	1.16 (1.07,1.25)
	2-3	1.52 (1.30,1.78)	1.47 (1.35,1.60)
	≥4	2.21 (1.66,2.94)	1.90 (1.58,2.29)
Asthma/bronchitis/ COPD	No	1	1
Asthma/bronchitis/ COPD	Yes	1.31 (1.16,1.48)	1.19 (1.12,1.27)
CHD	No	1	1
CHD	Yes	1.04 (0.79,1.37)	0.95 (0.81,1.11)
Depression/anxiety	No	1	1
Depression/anxiety	Yes	2.30 (2.07,2.56)	1.66 (1.58,1.75)
Diabetes	No	1	1
Diabetes	Yes	0.76 (0.60,0.97)	0.83 (0.73,0.95)
Variant period	Pre-VOC	1	1
	No dominant (1)	0.87 (0.78,0.97)	0.94 (0.89,0.99)
	Alpha	0.88 (0.73,1.06)	0.91 (0.84,0.99)
	No dominant (2)	0.66 (0.43,1.00)	0.94 (0.79,1.11)
Vaccinated at test	No	1	1
Vaccinated at test	Yes	0.91 (0.67,1.24)	0.90 (0.78,1.04)
Infection severity	Not hospitalised	1	1
Infection severity	Hospitalised	4.64 (3.81,5.66)	2.67 (2.32,3.06)

N number; OR odds ratio; CI confidence interval; SIMD Scottish Index of Multiple Deprivation; COPD chronic obstructive pulmonary disease; CVD cardiovascular disease; VOC variant of concern

There is NO Competing Interest.

SupplementaryFigure1.docx
Supplementary Figure 1. Heat map / radar map of current symptom clusters among people who had symptomatic COVID-19 infection
flatPells.pdf
Reporting Summary
flatPellepc.pdf
Editorial Policy Checklist

Download PDF

Journal Publication

published 12 Oct, 2022

Read the published version in Nature Communications →

Version 1

posted

You are reading this latest preprint version

Long-COVID in Scotland Study: a nationwide, population cohort study

Status:

Journal Publication

Version 1

Abstract

Introduction

Methods

STUDY DESIGN

DATA SOURCES

DEFINITIONS

OUTCOMES

STATISTICAL ANALYSES

Results

Discussion

Declarations

References

Tables

Additional Declarations

Supplementary Files

Status:

Journal Publication

Version 1